ALAlain Lortholary

Alain Lortholary

*This is an algorithmically generated author record based on publicly available information.

Alain Lortholary has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

    by Quentin Jacquinot, Sophie Paget-Bailly, Pierre Fumoleau, Gilles Romieu, Jean Yves Pierga, Marc Espié, Alain Lortholary, Jean Marc Nabholtz, Celine Faure Mercier, Iris Pauporté, et al.


  • Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

    by Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, Christelle Levy, Alain Lortholary, Alain Marre, Rémy Delva, Maria Rios, Patrice Viens, Étienne Brain, et al.


  • Métastases muqueuses digestives diffuses d’un carcinome lobulaire du sein

    by Alain Lortholary, Benoît Humeau, Hélène Castanié, Lemia Zgarni-Guillaumet, Claude El Kouri


  • Open Access

    GENESIS: a French national resource to study the missing heritability of breast cancer

    by Olga M. Sinilnikova, Marie-Gabrielle Dondon, Séverine Eon-Marchais, Francesca Damiola, Laure Barjhoux, Morgane Marcou, Carole Verny-Pierre, Valérie Sornin, Lucie Toulemonde, Juana Beauvallet, et al.

    Less than 20 % of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2 carry a pathogenic mutation in one of these two genes. The GENESIS (GENE SISter) study was designed to identify new breast cancer susceptibility genes in women attending cancer genetics clinics and with no BRCA1/2 mutation. The study involved the French national network of family cancer clinics. It was based on enrichment in genetic factors of the recruited population through case selection relying on familial criteria, but also on the consideration of environmental factors and endophenotypes like mammary density or tumor characteristics to assess potential genetic heterogeneity. One of the initial aims of GENESIS was to recruit affected sibpairs. Siblings were eligible when index cases and at least one affected sister were diagnosed with infiltrating mammary or ductal adenocarcinoma, with no BRCA1/2 mutation. In addition, unrelated controls and unaffected sisters were recruited. The enrolment of patients, their relatives and their controls, the collection of the clinical, epidemiological, familial and biological data were centralized by a coordinating center. Inclusion of participants started in February 2007 and ended in December 2013. A total of 1721 index cases, 826 affected sisters, 599 unaffected sisters and 1419 controls were included. 98 % of participants completed the epidemiological questionnaire, 97 % provided a blood sample, and 76 % were able to provide mammograms. Index cases were on average 59 years old at inclusion, were born in 1950, and were 49.7 years of age at breast cancer diagnosis. The mean age at diagnosis of affected sisters was slightly higher (51.4 years). The representativeness of the control group was verified. The size of the study, the availability of biological specimens and the clinical data collection together with the detailed and complete epidemiological questionnaire make this a unique national resource for investigation of the missing heritability of breast cancer, by taking into account environmental and life style factors and stratifying data on endophenotypes to decrease genetic heterogeneity.


  • Oncogénétique et tumeurs malignes rares de l’ovaire (TMRO)

    by A. Lortholary, A. Yvard, C. Dugast, A. Dubois

    Cette mise au point des connaissances actuelles permet d’individualiser certaines tumeurs malignes rares de l’ovaire (TMRO) et de préciser les indications de consultation d’oncogénétique pour les cliniciens. Contrairement aux cancers de l’ovaire classiques survenant à un âge jeune évoquant une mutation des gènes BRCA ou un syndrome de Lynch, la découverte d’une tumeur rare de l’ovaire même à un âge jeune n’évoque pas forcément une origine génétique et est le plus souvent sans rapport avec ces maladies génétiques. This development of the current knowledge allows individualizing some rare malignant ovarian tumors and specifying the indications of oncogenetics consultation for the clinicians. Contrary to the classic ovarian cancers arising at a young age evoking a BRCA mutation, the discovery of a rare ovarian tumor at a young age does not evoke necessarily a genetic origin and mostly without relationship with the BRCA genes.

  • Les hypercalcémies malignes: étude rétrospective sur 150 patients

    by A. Lortholary, C. El Kouri, J. -F. Ramée, N. Morineau, F. Maillet, C. Le Gouill, E. Terzidis-Mallat, O. Pauvreau, T. Cochery, R. Pioud-Martigny, et al.

    Une hypercalcémie est fréquemment retrouvée chez les patients atteints de cancer. L’objectif de cette étude était d’évaluer l’épidémiologie et les critères pronostiques des hypercalcémies d’origine tumorale sur une large série de patients atteints de cancer.

  • Open Access

    Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO)

    by Julie Lecarpentier, Catherine Noguès, Emmanuelle Mouret-Fourme, Marion Gauthier-Villars, Christine Lasset, Jean-Pierre Fricker, Olivier Caron, Dominique Stoppa-Lyonnet, Pascaline Berthet, Laurence Faivre, et al.

    Introduction: Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity. Methods: We assessed variation in BC risk according to factors related to pregnancies by location of mutation in the homogeneous risk region of BRCA1 and BRCA2 in 990 women in the French study GENEPSO by using a weighted Cox regression model. Results: Our results confirm the existence of the protective effect of an increasing number of full-term pregnancies (FTPs) toward BC among BRCA1 and BRCA2 mutation carriers (≥3 versus 0 FTPs: hazard ratio (HR) = 0.51, 95% confidence interval (CI) = 0.33 to 0.81). Additionally, the HR shows an association between incomplete pregnancies and a higher BC risk, which reached 2.39 (95% CI = 1.28 to 4.45) among women who had at least three incomplete pregnancies when compared with women with zero incomplete pregnancies. This increased risk appeared to be restricted to incomplete pregnancies occurring before the first FTP (HR = 1.77, 95% CI = 1.19 to 2.63). We defined the TMAP score (defined as the Time of Breast Mitotic Activity during Pregnancies) to take into account simultaneously the opposite effect of full-term and interrupted pregnancies. Compared with women with a TMAP score of less than 0.35, an increasing TMAP score was associated with a statistically significant increase in the risk of BC (P trend = 0.02) which reached 1.97 (95% CI = 1.19 to 3.29) for a TMAP score >0.5 (versus TMAP ≤0.35). All these results appeared to be similar in BRCA1 and BRCA2. Nevertheless, our results suggest a variation in BC risk associated with parity according to the location of the mutation in BRCA1. Indeed, parity seems to be associated with a significantly decreased risk of BC only among women with a mutation in the central region of BRCA1 (low-risk region) (≥1 versus 0 FTP: HR = 0.27, 95% CI = 0.13 to 0.55) (Pinteraction -3). Conclusions: Our findings show that, taking into account environmental and lifestyle modifiers, mutation position might be important for the clinical management of BRCA1 and BRCA2 mutation carriers and could also be helpful in understanding how BRCA1 and BRCA2 genes are involved in BC.


  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer

    by Alain Lortholary, Anne-Claire Hardy-Bessard, Thomas Bachelot, Gaëtan de Rauglaudre, Jérôme Alexandre, Hugues Bourgeois, Dominique Jaubert, Désiré Paraiso, Rémy Largillier

    To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine–paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1–14; paclitaxel 60 mg/m2, days 1, 8, and 15) or arm B (28-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1–5, 8–12, and 15–19; paclitaxel 80 mg/m2, days 1, 8, and 15). The primary endpoint was the incidence of dose reductions or delays >1 week for grade 3/4 toxicity. Secondary endpoints were efficacy and safety. All 130 randomized patients were evaluable for safety. Dose reduction or delay for grade 3/4 toxicity occurred in 39% of patients in arm A and 34% in arm B during cycles 1–6. In arm A, there were significantly more toxicity-related dose reductions (cycles 1–6: 82 vs. 67%, respectively; P = 0.05) and discontinuations (29 vs. 8%, respectively). Grade 3 diarrhea occurred in 12 and 0%, respectively, and grade 3 hand-foot syndrome in 12 versus 9%, respectively (grade 4 not applicable). There were no detectable differences in efficacy. Weekday capecitabine dosing with weekly paclitaxel may improve tolerability without a detrimental effect on efficacy, and merits further evaluation in patients suited to combination chemotherapy.


    • 1 October 2009
      • Vol. 29  (10) , 4195-200

    Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.

    by Béatrice Weber, Alain Lortholary, Françoise Mayer, Hugues Bourgeois, Hubert Orfeuvre, Martin Combe, Christian Platini, Jacques Cretin, Danièle Fric, Désiré Paraiso, et al.

    The GINECO group previously demonstrated that pegylated liposomal doxorubicin (PLD)-carboplatin combination was an effective and well-tolerated treatment for advanced ovarian cancer (AOC) patients in late relapse. The purpose of the present analysis was to confirm these results in a prospective cohort of late-relapsing AOC patients. Eighty-one consecutive patients received PLD 30 mg/m(2), followed by carboplatin (area under the curve) 5 mg min/ml, every 28 days for 6 courses or until progression. The objective response (OR) rate was 65.4%. The median progression-free survival (PFS) and overall survival (OS) were 13.6 months and 38.9 months, respectively. Haematological toxicities were more common than non-haematological toxicities. Non-hematologic adverse reactions were moderate and grade 3 palmar-plantar erythrodysesthesia was limited to one patient. No cardiotoxicity was observed and no toxic death occurred. These data support the clinical efficacy and tolerability of PLD in combination with carboplatin as second-line therapy for AOC patients in late relapse.